Market Overview

20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Share:

Gainers

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) shares moved upwards by 74.85% to $1.09 during Wednesday's pre-market session.

Edap TMS, Inc. (NASDAQ:EDAP) stock moved upwards by 27.85% to $2.80. The most recent rating by B. Riley, on Apr 15, is at Buy, with a price target of $6.

Genocea Biosciences, Inc. (NASDAQ:GNCA) shares rose 21.85% to $3.29.

Progyny, Inc. (NASDAQ:PGNY) shares moved upwards by 16.64% to $23.90. The most recent rating by Citigroup, on Mar 10, is at Buy, with a price target of $29.

Alcon, Inc. (NYSE:ALC) stock rose 11.79% to $59.55. The most recent rating by Wells Fargo, on Apr 9, is at Overweight, with a price target of $58.

Organovo Holdings, Inc. (NASDAQ:ONVO) stock rose 11.47% to $0.82.

Adamis Pharmaceuticals, Inc. (NASDAQ:ADMP) shares increased by 11.15% to $0.58.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares increased by 11.14% to $8.78.

Forward Pharma, Inc. (NASDAQ:FWP) stock moved upwards by 10.10% to $8.50.

Veru, Inc. (NASDAQ:VERU) shares moved upwards by 9.35% to $3.86.

 

Losers

KemPharm, Inc. (NASDAQ:KMPH) shares declined 13.70% to $0.25 during Wednesday's pre-market session.

Phio Pharmaceuticals, Inc. (NASDAQ:PHIO) shares declined 10.53% to $2.21.

Adaptive Biotechnologies, Inc. (NASDAQ:ADPT) stock fell 9.62% to $34.40.

Baudax Bio, Inc. (NASDAQ:BXRX) shares decreased by 9.43% to $3.17. The most recent rating by Oppenheimer, on May 11, is at Outperform, with a price target of $14.

bluebird bio, Inc. (NASDAQ:BLUE) stock decreased by 6.79% to $53. The most recent rating by RBC Capital, on May 13, is at Outperform, with a price target of $100.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) stock decreased by 6.10% to $0.77.

Acer Therapeutics, Inc. (NASDAQ:ACER) stock fell 5.87% to $3.53.

Helius Medical, Inc. (NASDAQ:HSDT) shares fell 5.69% to $0.61.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shares decreased by 5% to $11.41. The most recent rating by Wedbush, on Apr 3, is at Outperform, with a price target of $33.

ObsEva, Inc. (NASDAQ:OBSV) shares decreased by 4.76% to $3.40. The most recent rating by HC Wainwright & Co., on Mar 23, is at Buy, with a price target of $36.

 

Related Articles (EDAP + ARPO)

View Comments and Join the Discussion!

Posted-In: Healthcare Stocks Pre-Market MoversPre-Market Outlook Markets Movers Trading Ideas